VIVUS Reports First Quarter 2020 Financial Results
06 mai 2020 16h05 HE
|
VIVUS, Inc.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported...
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
01 mai 2020 08h40 HE
|
VIVUS, Inc.
CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after...
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
01 mai 2020 08h35 HE
|
VIVUS, Inc.
CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH...
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
03 avr. 2020 15h00 HE
|
VIVUS, Inc.
CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered...
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
01 avr. 2020 09h02 HE
|
VIVUS, Inc.
CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with...
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
31 mars 2020 07h30 HE
|
VIVUS, Inc.
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk...
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
03 mars 2020 16h05 HE
|
VIVUS, Inc.
- Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported...
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
02 mars 2020 07h30 HE
|
VIVUS, Inc.
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif., March 02, 2020 (GLOBE...
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
19 févr. 2020 07h30 HE
|
VIVUS, Inc.
- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the...
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
18 févr. 2020 07h30 HE
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019...